|
Predicting outcomes in renal cell cancer: The role of single nucleotide polymorphisms (SNPs). |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Astellas Oncology; Aventis Pharma; Bayer; Bristol-Myers Squibb; Genentech; Janssen; Pierre Fabre; Roche; Sanofi |
Research Funding - Aventis Pharma; Janssen; Sanofi |
Travel, Accommodations, Expenses - Astellas Oncology |